July 6th, 2021 | 11:34 CEST
Bayer, XPhyto Therapeutics, Pfizer: Here comes the blockbuster of the 4th wave
Table of contents:
"[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.
Bayer: Value - and what else?
Bayer is anything but a growth company. Nevertheless, the Leverkusen-based Company is currently regarded by many stock market experts as an exciting pick. Why? The Company is the market leader, shines with good figures and has largely shaken off the glyphosate dispute, which has been a burden for many years, at least in its share price. Added to this is a dividend that currently convinces many investors with more than a 5% dividend yield. While Bayer offers no hope of being the next multiplier, a hefty dividend is a good argument, especially for risk-averse investors.
In addition to its health care offerings, Bayer also operates in the agricultural technology sector, benefiting from rising commodity prices and the improving inflationary environment. The stock is not hot, but it is a solid one. Over a year, the stock has returned more than 20%. There is not so much fantasy in Bayer at the moment, but there is a lot of value.
XPhyto: Next-generation PCR test comes to Berlin
On the other hand, the young Canadian Company XPhyto Therapeutics, which does business in Germany and elsewhere, is more on the growth path. XPhyto has developed a method that enables PCR tests to deliver meaningful results within 20-25 minutes. After only a little more time than error-prone antigen tests, XPhyto's solution provides PCR-quality certainty. Airports or hotels, in particular, could take advantage of the offer. Given the upcoming wave of travel, XPhyto's solution could strike a nerve.
The Company signed an agreement with ten test centers at the end of June and sent the first tests to Berlin. In addition to test kits, XPhyto offers solutions to help the human body better absorb medical agents, such as patches and solutions, and is developing drugs. In addition to a neurological drug, the Canadians are also working with psychedelic agents. The stock has been on a dive for weeks. While this may not attract investors at first glance, XPhyto Therapeutics offers an exciting product mix. The PCR tests could become a bread-and-butter business in a quarter-wave, and the activities around psychoactive compounds spark the imagination. Investors can bookmark XPhyto - the list of potential catalysts for a turnaround is long.
Pfizer: What can the Corona profiteer do?
While fantasy lurks in XPhyto, Pfizer's stock is an open book: the Company is one of the largest pharmaceutical companies in the world, making a name for itself primarily with several blockbuster drugs, each of which generates more than USD 1 billion in annual sales. Pfizer also benefits from its collaboration with BioNTech on the Covid-19 vaccine. Still, the stock has not really gotten off the ground in the past year - the price tags show a yield of just 9%. In addition, there is a dividend of around 3.5% measured against the current share price. The Pfizer share will no longer be a high-flyer but can be a solid foundation in a conservative portfolio.
Nevertheless, for private investors especially, it can make sense to invest a little more speculatively in the pharmaceutical, laboratory diagnostics, and biotech sectors. While relevant returns on Pfizer and Bayer can only be achieved with large position sizes, courageous speculators can profit with small investments in XPhyto Therapeutics. The rapid PCR test with results from 20 minutes could become the blockbuster of the fourth wave. Given a market capitalization of less than EUR 100 million, the share price is likely to react more clearly to such a development than it would to a big player like Pfizer and Co.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.